Antibacterial drugs: key market research findings
- Increase in awareness and patient assistance programs
- Rise in the prevalence of beta-lactams
Technavio has added a new market research report on the global antibacterial drugs market, to its drugs portfolio. The global antibacterial drugs market is expected to grow at a modest CAGR of around 1% because of the decline in the research activities in the field of antibiotic studies though there is an increase in the prevalence of infectious diseases across the world. APAC dominates the global market for antibacterial drugs, accounting for around 49% of the total market share. Increased demand for better healthcare infrastructure and rise in aging population are major factors driving the market’s growth in this region.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
“Increased awareness about infectious diseases has reduced the chances of several critical damages to the body. Several governments and NGOs are carrying out awareness programs regarding the ill-effects of various infections and health risks. For instance, the US Department of Health and Human Services has developed Healthy People 2020, which aims at the prevention and treatment of infectious diseases. There are several other awareness programs for healthy hygiene, pneumonia, antibiotic usage across the world. Also, several vendors and drug suppliers are providing financial assistance to patients to buy antibacterial drugs,” says Imran Mushtaq, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
Antibacterial drugs are widely used in the treatment of various infections like sexually transmitted infections, respiratory infections, skin infections, urinary tract infections, and meningitis. The largest revenue contributor of the antibacterial drugs market is the beta-lactam segment with a market share of more than 54%. Beta-lactam is categorized into different antibacterial classes such as penicillins, carbapenems, monobactams, and cephalosporins.
The leading vendors in the global antibacterial drugs market include Allergan, GSK, Merck, Pfizer, Sandoz, and Teva Pharmaceuticals. The unavailability of effective treatment options and the increased development of drug resistance is leading to an unmet medical need in the market, which has led to an increase in R&D. Companies such as Cempra, Actelion, Theravance Biopharma, etc. are expected to enter the market and attain considerable market shares, thereby increasing the competition in the market.
A more detailed analysis is available in the Technavio report, Global Antibacterial Drugs Market 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
